Cyclacel Pharmaceuticals (CYCC) News Today $0.32 -0.01 (-4.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.comDecember 17, 2024 | americanbankingnews.comCyclacel Pharmaceuticals Faces Potential Delisting from Nasdaq Stock Market Due to Minimum Bid Price NoncomplianceDecember 16, 2024 | americanbankingnews.comCyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsDecember 5, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 19, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsNovember 14, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsNovember 13, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comCyclacel Pharmaceuticals granted extension for regain Nasdaq complianceOctober 25, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleOctober 24, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumOctober 23, 2024 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Insider Trading ActivityOctober 20, 2024 | benzinga.comCyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumOctober 9, 2024 | globenewswire.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comCyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudySeptember 25, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comCyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterSeptember 3, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Second Quarter 2024 Financial ResultsAugust 7, 2024 | globenewswire.comCyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsJune 26, 2024 | globenewswire.comCyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingJune 4, 2024 | globenewswire.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | investorplace.comCyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesMay 2, 2024 | globenewswire.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | msn.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | investorplace.comCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesApril 30, 2024 | globenewswire.comCyclacel Pharmaceuticals Shares Up 72% After Hours on Withdrawal of OfferingApril 29, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Hit All-Time Low on Planned Equity SaleApril 26, 2024 | marketwatch.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near FutureApril 25, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerApril 1, 2024 | globenewswire.comCyclacel Pharmaceuticals IncMarch 27, 2024 | money.usnews.comCyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finance.yahoo.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023March 19, 2024 | msn.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditMarch 6, 2024 | globenewswire.comCyclacel Pharmaceuticals, Inc. (CYCCP)February 22, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 20, 2024 | globenewswire.comCyclacel Pharmaceuticals Inc. (UXI.SG)February 15, 2024 | finance.yahoo.comCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequirementJanuary 8, 2024 | finance.yahoo.comWhy Cyclacel Pharmaceuticals (CYCC) Shares Are Getting ObliteratedDecember 22, 2023 | msn.comCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq RulesDecember 22, 2023 | finance.yahoo.comTrading was temporarily halted for "CYCC" at 09:12 AM with a stated reason of "LULD pause."December 22, 2023 | marketbeat.comBrookline Capital Downgrades Cyclacel Pharmaceuticals (CYCC)December 20, 2023 | msn.comTrading was temporarily halted for "CYCC" at 07:12 PM with a stated reason of "News pending."December 18, 2023 | marketbeat.comCyclacel Pharmaceuticals Stock (NASDAQ:CYCC) Dividends: History, Yield and DatesDecember 15, 2023 | benzinga.comCyclacel Pharmaceuticals Announces Reverse Stock SplitDecember 12, 2023 | finance.yahoo.comCyclacel Pharmaceuticals regains compliance with Nasdaq listing rulesNovember 30, 2023 | msn.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 28, 2023 | benzinga.com Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol CYCC Media Mentions By Week CYCC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYCC News Sentiment▼0.000.60▲Average Medical News Sentiment CYCC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYCC Articles This Week▼20▲CYCC Articles Average Week Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Brainstorm Cell Therapeutics News Today Ensysce Biosciences News Today Biofrontera News Today Aytu BioPharma News Today Addex Therapeutics News Today Viracta Therapeutics News Today Conduit Pharmaceuticals News Today CERo Therapeutics News Today Soligenix News Today Coeptis Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYCC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts